Physician

Manmeet Mangat, MD

According to 2025 Medicare claims, Manmeet Mangat, MD (NPI: 1174559512) practices hematology/oncology in the Midland, TX market, with the plurality of this provider's patient population coming from Midland, TX. This provider's primary affiliated billing organization is TEXAS ONCOLOGY PA (NPI: 1811944101; TIN: 752131429) and primary practice location at 79701-5849.

Mangat's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 574 traditional Medicare patients, billed 166,765 HCPCS/CPT codes, and received $2,748,545 in Medicare payments. The top billing code was 99214 (Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more). Part D data shows 1,738 prescription claims across 260 beneficiaries totaling $6,330,035 in drug costs, led by Xtandi (Enzalutamide). 2023 DME data shows 72 claims. Open Payments data shows 10 records totaling $252,031. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has changed little. Concurrently, Part D prescription costs have moved sharply higher in recent years, from $1,345,985 to $6,330,035. In contrast, DME billing represents a smaller volume and started with an early spike, then settled into a lower baseline, moving from $29,581 to $1,136.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	565	221,231	$2,278,921
2016	782	179,611	$2,307,518
2017	761	104,684	$1,745,142
2018	738	142,453	$2,492,914
2019	712	133,537	$2,158,860
2020	623	97,790	$2,124,277
2021	622	77,096	$1,713,390
2022	747	146,045	$2,724,495
2023	601	122,877	$2,173,973
2024	574	166,765	$2,748,545

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	163	945	$1,345,985
2016	191	1,102	$1,710,390
2017	205	1,273	$2,035,594
2018	217	1,485	$2,632,114
2019	225	1,480	$2,288,983
2020	238	1,488	$3,239,488
2021	222	1,506	$3,431,478
2022	263	1,787	$3,896,183
2023	259	1,938	$6,342,729
2024	260	1,738	$6,330,035

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	76	576	$64,414
2016	24	210	$10,098
2017	N/R	N/R	N/R
2018	N/R	N/R	N/R
2019	N/R	12	$2,201
2020	N/R	N/R	N/R
2021	N/R	N/R	N/R
2022	N/R	48	$2,208
2023	N/R	72	$13,777
2024	N/R	N/R	N/R

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
99214	Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more	189	442	$90
99213	Established patient office or other outpatient visit with low level od decision making, if using time, 20 minutes or more	281	495	$59
80053	Blood test, comprehensive group of blood chemicals	303	1,185	$10
36415	Insertion of needle into vein for collection of blood sample	331	1,428	$9
85025	Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count	321	1,318	$8

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Xtandi	Enzalutamide	75	2,250	$1,043,249
Revlimid	Lenalidomide	46	1,253	$882,662
Ibrance	Palbociclib	25	700	$385,733
Cabometyx	Cabozantinib S-Malate	16	480	$382,772
Cerdelga	Eliglustat Tartrate	12	336	$378,658

Top 5 DME services in 2024

No connected or detailed DME service-level records for 2024.

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	7	$6,017	Incyte Corporation
Research Payments	Reported research-related payment or transfer-of-value amount.	3	$246,014	Mirati Therapeutics, Inc.
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Manmeet Mangat, MD?

Tedicare shows public-source Medicare data for Manmeet Mangat, MD (NPI 1174559512), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Manmeet Mangat, MD have ACO affiliation data?

No ACO affiliation record is shown in the available Tedicare data for this profile.

What billing organization is linked to Manmeet Mangat, MD?

Manmeet Mangat, MD is linked to TEXAS ONCOLOGY PA (billing NPI 1811944101) in the available physician profile data.

Does Manmeet Mangat, MD have Open Payments data?

Manmeet Mangat, MD has 10 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.